Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
Patients with focal epileptic seizures with or without generalization who are at present
treated with one or two antiepileptic drugs are eligible for this study, provided that they
fulfill all inclusion criteria and none of the exclusion criteria. Following a baseline phase
of 8 weeks duration, the patients are randomised and they receive an initial daily dose of 50
mg zonisamide during the first week. The daily dose is then increased to 200 mg zonisamide in
group A or 400 mg zonisamide in group B, respectively. After eight weeks of treatment, the
daily dose in group A can be increased to 300 mg in case of insufficient efficacy. Control
assessments are performed at the beginning of the study and at the end of the prospective
baseline phase, if applicable and after 4, 8, 12, and 16 weeks. At the end of the first,
second, and third treatment week, and at the end of week six, the patient is additionally
contacted by telephone. Efficacy and safety parameters are assessed at baseline, during all
control visits, and at the end of the study.
Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial
The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg
- 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a
body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.